Journal of Cardiovascular Imaging

  • 제22권2호
  • /
  • Pages.95-97
  • /
  • 2014
  • /
  • 2586-7210(pISSN)
  • /
  • 2586-7296(eISSN)
한국심초음파학회 (Korean Society of Echocardiography)
권호 표지
DOI QR코드

DOI QR Code

EFFICACY OF INHALED ILOPROST IN COR PULMONALE AND SEVERE PULMONARY HYPERTENSION ASSOCIATED WITH TUBERCULOUS DESTROYED LUNG

  • Park, Yae Min (Division of Cardiology, Heart Center, Gachon University Gil Medical Center) ;
  • Chung, Wook-Jin (Division of Cardiology, Heart Center, Gachon University Gil Medical Center) ;
  • Lee, Sang Pyo (Division of Pulmonology, Gachon University Gil Medical Center) ;
  • Choi, Deok Young (Gachon Cardiovascular Research Institute, Gachon University Gil Medical Center) ;
  • Baek, Han Joo (Division of Rheumatology, Gachon University Gil Medical Center) ;
  • Jung, Sung Hwan (Division of Pulmonology, Gachon University Gil Medical Center) ;
  • Choi, In Suck (Division of Cardiology, Heart Center, Gachon University Gil Medical Center) ;
  • Shin, Eak Kyun (Division of Cardiology, Heart Center, Gachon University Gil Medical Center)
  • 투고 : 2013.11.24
  • 심사 : 2014.05.15
  • 발행 : 2014.06.27
⟨ 이전 논문 다음 논문 ⟩

초록

Chronic obstructive pulmonary disease (COPD) is one of the causes of cor pulmonale. Cor pulmonale patients with pulmonary hypertension have a significant lower survival rate than patients without. However, there is no conclusive treatment options in cor pulmonale and pulmonary hypertension associated with COPD until now. We report a patient with cor pulmonale and pulmonary hypertension associated with severe form of COPD and tuberculous destroyed lung who achieved marked clinical, functional and echocardiographic hemodynamic improvements with inhaled iloprost for six months.

키워드

참고문헌

  1. Oswald-Mammosser M, Weitzenblum E, Quoix E, Moser G, Chaouat A, Charpentier C, Kessler R. Prognostic factors in COPD patients receiving long-term oxygen therapy. Importance of pulmonary artery pressure. Chest 1995;107:1193-8. https://doi.org/10.1378/chest.107.5.1193
  2. Hoeper MM, Schwarze M, Ehlerding S, Adler-Schuermeyer A, Spiekerkoetter E, Niedermeyer J, Hamm M, Fabel H. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med 2000;342:1866-70. https://doi.org/10.1056/NEJM200006223422503
  3. Opitz CF, Wensel R, Winkler J, Halank M, Bruch L, Kleber FX, Höffken G, Anker SD, Negassa A, Felix SB, Hetzer R, Ewert R. Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension. Eur Heart J 2005;26:1895-902. https://doi.org/10.1093/eurheartj/ehi283
  4. Boeck L, Tamm M, Grendelmeier P, Stolz D. Acute effects of aerosolized iloprost in COPD related pulmonary hypertension - a randomized controlled crossover trial. PLoS One 2012;7:e52248. https://doi.org/10.1371/journal.pone.0052248
  5. Hegewald MJ, Elliott CG. Sustained improvement with iloprost in a COPD patient with severe pulmonary hypertension. Chest 2009;135:536-7. https://doi.org/10.1378/chest.08-1515
  6. Barberà JA, Blanco I. Pulmonary hypertension in patients with chronic obstructive pulmonary disease: advances in pathophysiology and management. Drugs 2009;69:1153-71. https://doi.org/10.2165/00003495-200969090-00002
  7. Dernaika TA, Beavin M, Kinasewitz GT. Iloprost improves gas exchange and exercise tolerance in patients with pulmonary hypertension and chronic obstructive pulmonary disease. Respiration 2010;79:377-82. https://doi.org/10.1159/000242498
  8. Wilkens H, Bauer M, Forestier N, Konig J, Eichler A, Schneider S, Schafers HJ, Sybrecht GW. Influence of inhaled iloprost on transpulmonary gradient of big endothelin in patients with pulmonary hypertension. Circulation 2003;107:1509-13. https://doi.org/10.1161/01.CIR.0000056104.49686.4B
  9. Opitz CF, Wensel R, Bettmann M, Schaffarczyk R, Linscheid M, Hetzer R, Ewert R. Assessment of the vasodilator response in primary pulmonary hypertension. Comparing prostacyclin and iloprost administered by either infusion or inhalation. Eur Heart J 2003;24:356-65.